Insulin secretion is decreased in non-diabetic individuals with hypomagnesaemia.

Background: Magnesium modulates insulin-mediated glucose uptake but data regarding its role in insulin secretion are scarce; therefore, in this study we determined whether decreased serum magnesium levels are associated with the impairment of insulin secretion in non-diabetic individuals.
Methods: A total of 182 apparently healthy subjects, men and non-pregnant women, 18-65 years of age, were enrolled in a population-based cross-sectional study and allocated to groups with hypomagnesaemia and normomagnesaemia. The groups in the study were subsequently stratified according to glucose status: normal glucose tolerance, impaired fasting glucose, and impaired glucose tolerance. Insulin secretion was evaluated by the first and second phases of insulin secretion.
Results: The Spearman coefficient between serum magnesium and the first and second phases of insulin secretion showed a significant positive correlation in the overall (r = 0.265, p < 0.0005; r = 0.541, p < 0.0005), normal glucose tolerance (r = 0.369, p = 0.001; r = 0.618, p < 0.0005), impaired fasting glucose (r = 0.320, p = 0.02; r = 0.449, p = 0.001), and impaired glucose tolerance (r = 0.129, p = 0.37; r = 0.522, p < 0.0005) groups. The multivariate linear regression analysis showed a significant association between serum magnesium levels and the first and second phases of insulin secretion: for the entire groups [B = 75.2; 95% confidence interval (CI) 27.6-122.7; B = 25.4; 95% CI 16.4-34.3], normal glucose tolerance (B = 129.6, 95% CI 38.1-221.1; B = 40.3, 95% CI 23.7-56.8), impaired fasting glucose (B = 75.2, 95% CI 27.6-122.7; B = 15.1, 95% CI 4.2-30.2), and impaired glucose tolerance (B = 57.4, 95% CI 23.5-138.3; B = 25.4, 95% CI 16.4-34.3) groups.
Conclusions: Our results show that hypomagnesaemia is associated with the decrease of the first and second phases of insulin secretion in non-diabetic subjects with hypomagnesaemia.
(Copyright © 2011 John Wiley & Sons, Ltd.)